TOSCA

Three Or Six Colon Adjuvant

A RANDOMIZED TRIAL INVESTIGATING THE ROLE OF FOLFOX-4 OR XELOX (3 VERSUS 6 MONTHS) REGIMEN DURATION AND BEVACIZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE II/III COLON CANCER

· NEWSLETTER

Scarica il file